COVID-19: Vaccines and Therapeutics
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration extended the shelf life for the monoclonal antibody therapy etesevimab, which currently must be administered with bamlanivimab.
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., recommended a single COVID-19 vaccine booster dose at least six months after completing an initial mRNA COVID-19 vaccine series for certain individuals at risk for severe COVID-19, as proposed by her agency’s Advisory…
New data from Pfizer is indicating high efficacy for its COVID-19 vaccine as a booster, as well as its effectiveness among the 5-11 age group.
As deaths due to COVID-19 increase disproportionately in rural communities, farmers, ranchers and other rural residents are opening up about the hardships they’ve faced.
The Texas hospital is making house calls to educate people about the vaccines and administers shots.
This presentation helps health care leaders talk with community groups about the vaccine and answer some frequently asked questions.
The Food and Drug Administration authorized administering a single booster dose of the Moderna and Johnson & Johnson COVID-19 vaccines to eligible individuals, and authorized eligible recipients of all three authorized COVID-19 vaccines to receive a different COVID-19 vaccine for their initial…
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted unanimously to recommend a single COVID-19 vaccine booster dose at least six months after completing an initial mRNA COVID-19 vaccine series, in the same risk groups for whom CDC recommended a Pfizer…
A mix-and-match vaccine regimen is permissible for international travelers entering the U.S., according to updated Centers for Disease Control and Prevention guidance.
Treatment with subcutaneous interferon beta-1a plus remdesivir was not superior to treatment with remdesivir alone in a clinical trial that enrolled 969 hospitalized adults with COVID-19 pneumonia in the United States, Japan, Mexico, Singapore and South Korea, the National Institutes of Health…